Will Insurance Cover Zepbound for Sleep Apnea? Coverage Rules in 2026

Key Takeaways

• Yes, many insurance plans now cover Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, following the FDA's December 2024 approval.
• Medicare Part D added Zepbound coverage for OSA in 2025, the first time Medicare has covered a GLP-1/GIP for any obesity-adjacent indication.
• Coverage typically requires BMI 30+, an apnea-hypopnea index (AHI) of 15 or higher, and concurrent or documented intolerance of positive airway pressure (PAP) therapy.
• Prior authorization is required across most plans, including Medicare. Approval criteria are stricter than for weight-loss-only coverage.
• The SURMOUNT-OSA trial (Malhotra et al., NEJM 2024) showed Zepbound reduced AHI by 25 to 29 events per hour in patients with obesity and moderate-to-severe OSA.

Direct answer (40-60 words)

Yes, many insurance plans cover Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, following the FDA's December 2024 approval. Coverage usually requires prior authorization with documentation of BMI 30+, an apnea-hypopnea index of 15 or higher, and current or attempted PAP therapy. Medicare Part D plans began covering Zepbound for OSA in 2025.

Table of contents

1. The 30-second answer
2. The FDA approval that opened OSA coverage
3. What the SURMOUNT-OSA trial showed
4. Commercial insurance coverage for Zepbound + OSA
5. Medicare Part D coverage for Zepbound + OSA
6. Medicaid coverage for Zepbound + OSA
7. Prior authorization criteria
8. What to do if your plan denies it
9. Cost with and without coverage
10. FAQ
11. Sources
12. Footer disclaimers

The FDA approval that opened OSA coverage

In December 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity. This was the first GLP-1/GIP receptor agonist approved for sleep apnea, and the first FDA approval of any drug for OSA in many years (FDA, 2024).

The approval matters for insurance for two reasons:

Reason 1: It changed Zepbound from a weight-loss-only drug to a multi-indication drug. Insurance coverage rules differ between obesity-only drugs (often excluded under federal Medicare statute) and multi-indication drugs (often covered if used for the non-obesity indication).

Reason 2: It created a new path to coverage for patients who already have OSA. Patients with OSA who couldn't get Zepbound covered for weight loss alone could now apply for coverage based on the OSA indication, which has different formulary rules.

The approval doesn't automatically mean every plan covers Zepbound for OSA. Plans set their own rules within the FDA approval framework. But the approval gave plans the option to cover, and most large commercial insurers and Medicare Part D plans took it.

What the SURMOUNT-OSA trial showed

The SURMOUNT-OSA trial (Malhotra et al., NEJM 2024) was the registration study that supported the FDA approval. It enrolled 469 adults with obesity and moderate-to-severe OSA, randomized to tirzepatide 10 or 15 mg weekly or placebo for 52 weeks.

Primary outcome: change in apnea-hypopnea index (AHI), the standard measure of sleep apnea severity. AHI counts the number of breathing pauses or shallow breaths per hour of sleep. Moderate OSA is AHI 15 to 29; severe OSA is AHI 30+.

Results:

• Tirzepatide group (PAP-eligible cohort): AHI reduced by 25.3 events per hour (vs 5.3 with placebo).
• Tirzepatide group (PAP-using cohort): AHI reduced by 29.3 events per hour (vs 5.5 with placebo).
• About 50% of tirzepatide patients achieved an AHI reduction sufficient to be considered remission of OSA.

Why it worked: OSA is strongly linked to obesity. Excess fat around the upper airway and chest contributes to airway collapse during sleep. Tirzepatide's substantial weight loss (about 18-20% of body weight in the trial) reduced the anatomical drivers of OSA.

The trial wasn't designed to replace PAP therapy. Many participants stayed on PAP throughout. But it established that pharmacologic treatment can meaningfully improve OSA in patients with obesity, opening a new treatment pathway.

Commercial insurance coverage for Zepbound + OSA

As of April 2026, most large commercial insurers cover Zepbound for OSA on most plans. Coverage policies follow a similar pattern across BlueCross BlueShield, UnitedHealthcare, Aetna, and Cigna:

Insurer	Coverage status for OSA	Common requirements
BlueCross BlueShield	Covered with PA	BMI 30+, AHI 15+, current or trial of PAP
UnitedHealthcare	Covered with PA	BMI 30+, AHI 15+, sleep study within 12 months
Aetna	Covered with PA	BMI 30+, moderate-to-severe OSA documented, PAP intolerance or use
Cigna	Covered with PA	BMI 30+, AHI 15+, sleep medicine specialist involvement
Kaiser Permanente	Coverage varies by region	Region-specific criteria, often includes sleep clinic referral

The pattern: BMI threshold + sleep study + PAP element. The insurance logic is that Zepbound is for patients whose OSA is severe enough to matter clinically and who have already engaged with standard treatment.

Coverage tends to be on Tier 3 or specialty tier, with copays of $40 to $400 per fill depending on the plan. The Eli Lilly Zepbound Savings Card can reduce eligible commercial-insurance copays to as little as $25 per fill, with maximum benefit of about $469 per fill, for up to 13 fills (Eli Lilly, 2026 program terms).

Self-funded employer plans can carve out OSA coverage even if the insurer's standard formulary covers it. If your employer plan explicitly excludes weight-loss medications, the OSA indication may also be excluded depending on how the carve-out is written. Read your Summary of Benefits and Coverage carefully.

Medicare Part D coverage for Zepbound + OSA

Medicare Part D's coverage for Zepbound for OSA is the most clinically significant change of 2025.

Federal statute (Medicare Modernization Act, 2003) prohibits Medicare from covering medications used solely for weight loss. Before the FDA OSA approval, Zepbound had only the weight-management indication, which made it excluded from Part D.

The OSA approval changed the calculus. Medicare doesn't have a federal exclusion for sleep apnea medications. Following the December 2024 FDA approval, CMS clarified that Part D plans could cover Zepbound when prescribed for the OSA indication (CMS guidance, 2025).

Medicare Part D coverage for Zepbound + OSA (as of April 2026):

• Most major Part D plans cover Zepbound for OSA, with prior authorization.
• Specialty-tier copays typically run $200 to $500 per fill, depending on the plan and coverage gap status.
• The Eli Lilly Zepbound Savings Card does not work for Medicare patients (federal anti-kickback rules).
• Coverage requires documented OSA diagnosis (AHI 15+), BMI 30+, and concurrent or attempted PAP therapy.

What Medicare still doesn't cover for Zepbound:

• Weight loss alone (no qualifying OSA or other approved indication).
• Cardiovascular risk reduction (Wegovy has this Medicare coverage; Zepbound does not yet).
• Off-label uses.

For Medicare patients with OSA and obesity, this is the first time a GLP-1/GIP has been a covered option. Talk to your sleep medicine specialist or primary care provider about whether you qualify.

Medicaid coverage for Zepbound + OSA

State Medicaid coverage for Zepbound + OSA is still evolving. As of April 2026:

• States already covering Zepbound for weight management generally cover it for OSA on the same or stricter terms.
• States that don't cover Zepbound for weight management are mixed on OSA coverage. Some have added the OSA indication; others haven't.
• Prior authorization requirements are generally similar to commercial plans (BMI 30+, AHI 15+, PAP element).

The federal landscape is also shifting. CMS has indicated openness to broader Medicaid coverage of OSA pharmacotherapy, but federal mandates haven't been issued. Check your state's Medicaid formulary directly for the most current information.

Prior authorization criteria

The PA submission for Zepbound for OSA typically requires:

Documentation 1: Sleep study results. A polysomnography (PSG) or home sleep apnea test (HSAT) within the past 12 months showing AHI of 15 or higher. Some plans accept older sleep studies if the diagnosis is established.

Documentation 2: BMI. Current BMI 30 or higher, calculated from height and weight measured in the provider's office (not self-reported).

Documentation 3: PAP element. Either current PAP use (documented through machine compliance data, typically 4+ hours per night for 70%+ of nights), or documented PAP intolerance (failed mask fittings, claustrophobia, persistent symptoms despite use), or active enrollment in a PAP program.

Documentation 4: Sleep medicine involvement. Many plans require the prescription or PA submission to involve a sleep medicine specialist, a pulmonologist, or a board-certified sleep physician.

Documentation 5: Lifestyle counseling. Some plans require documented dietary and behavioral counseling, similar to weight-loss PA criteria.

PA approval rates for Zepbound + OSA are generally higher than for Zepbound + weight loss alone, because the FDA-approved indication is more straightforward and the clinical rationale is well-supported by SURMOUNT-OSA. A 2025 analysis of early Zepbound + OSA PAs found approval rates around 65 to 75% on first submission (industry estimate; published data still limited).

What to do if your plan denies it

Three paths back to coverage:

Path 1: Peer-to-peer appeal. Your provider speaks with the insurance medical director by phone. Approval rates on peer-to-peer appeals for GLP-1 denials run 50 to 70% in published studies (Khan et al., Health Affairs 2023).

Path 2: Formal written appeal. Provider submits additional documentation. Plans must respond within 30 days for standard appeals, 72 hours for urgent.

Path 3: External review. Federal law gives commercial-plan patients the right to an independent external review (Affordable Care Act, Section 2719). The reviewer's decision is binding.

For Medicare patients, the appeals process runs through CMS's redetermination and reconsideration steps, with eventual access to an Administrative Law Judge hearing if needed.

While the appeal works through, you can pay cash, use LillyDirect ($349 to $499 per month for self-pay vials), or look at compounded tirzepatide as a separate path.

Cost with and without coverage

Coverage scenario	Typical monthly cost
Commercial insurance + savings card (eligible)	$25 to $150
Commercial insurance, no savings card	$40 to $400
Medicare Part D (OSA indication, after deductible)	$200 to $500
LillyDirect self-pay (single-dose vials)	$349 to $499
Cash price at retail pharmacy	About $1,059
Compounded tirzepatide (licensed pharmacy)	$179 to $329

Two factors swing the cost most: whether your plan covers Zepbound at all, and whether you qualify for the manufacturer savings card. Patients on Medicare can't use the savings card, which makes Medicare Part D copays meaningfully higher than commercial copays even when both plans cover the drug.

For patients who don't qualify for any covered option, internal link: see what insurance covers Zepbound for broader coverage strategies.

FAQ

Will insurance cover Zepbound for sleep apnea? Yes, most large commercial insurance plans cover Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, following the December 2024 FDA approval. Prior authorization is required, typically with documentation of BMI 30+, AHI 15+, and concurrent or attempted PAP therapy.

Does Medicare cover Zepbound for sleep apnea? Yes. Medicare Part D plans began covering Zepbound for OSA in 2025, after the FDA approval. Coverage requires prior authorization. Specialty-tier copays typically run $200 to $500 per fill. The manufacturer savings card does not work for Medicare patients.

What does my plan need for Zepbound + OSA prior authorization? A sleep study showing AHI 15 or higher (within 12 months for most plans), BMI 30 or higher measured in office, current or attempted PAP therapy, and a sleep medicine specialist or primary care provider's clinical rationale.

Do I have to use a CPAP machine before insurance covers Zepbound? Most plans require either current PAP use, documented PAP intolerance, or active enrollment in a PAP program. The exact wording varies. Some plans accept "trial of PAP" with documented difficulty as sufficient.

What if I already lost weight on PAP and my AHI improved? The PA submission documents your situation at the time of prescription. If your AHI was 15+ at diagnosis but has since improved, your provider can document the original diagnosis. However, plans may want recent sleep study data, and a current AHI below 15 could affect approval. Discuss with your sleep specialist.

Is Zepbound for sleep apnea different from Zepbound for weight loss? Same medication, same dose ladder (2.5/5/7.5/10/12.5/15 mg weekly), same titration. The difference is the FDA-approved indication on the prescription, which determines insurance coverage rules.

Will Zepbound replace my CPAP machine? Not automatically. SURMOUNT-OSA showed about half of tirzepatide patients achieved remission of OSA, but many still benefited from concurrent PAP therapy. Decisions about reducing or stopping PAP should involve your sleep medicine provider and follow-up sleep studies.

How much does Zepbound for sleep apnea cost with insurance? With commercial insurance and the manufacturer savings card, eligible patients pay as little as $25 per fill. Without the savings card, copays typically run $40 to $400 depending on tier and deductible. Medicare patients pay $200 to $500 in specialty-tier copays.

Can my primary care provider prescribe Zepbound for sleep apnea? In most cases yes, but some insurance plans require a sleep medicine specialist's involvement in the PA process. A sleep study is usually required regardless of who prescribes.

Does the Zepbound savings card work for the OSA indication? The Eli Lilly Zepbound Savings Card applies to FDA-approved indications. As of 2026 program terms, it works for both weight management and OSA when prescribed for those approved uses, for patients with commercial insurance. It does not work for Medicare or Medicaid patients.

What if my AHI is below 15? Mild OSA (AHI 5 to 14) is generally not a covered indication for Zepbound under current insurance criteria. The FDA approval was specifically for moderate-to-severe OSA. Patients with mild OSA may still pursue coverage through the weight-management indication if they meet BMI criteria.

How long does it take for Zepbound to improve sleep apnea? Improvement parallels weight loss. SURMOUNT-OSA measured outcomes at 52 weeks, with significant AHI reduction by 20 weeks. Most patients see meaningful sleep improvement within 4 to 6 months, with continued improvement through 12 months.

Sources

1. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205.
2. U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. FDA News Release, December 2024.
3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
4. Khan A, et al. Peer-to-peer appeal outcomes for GLP-1 denials. Health Aff (Millwood). 2023;42(8):1115-1123.
5. Eli Lilly. Zepbound (tirzepatide) Prescribing Information, revised 2024.
6. Eli Lilly. Zepbound Savings Card Terms and Conditions, accessed April 2026.
7. Centers for Medicare & Medicaid Services. Part D Coverage Guidance for Tirzepatide for Obstructive Sleep Apnea, 2025.
8. American Academy of Sleep Medicine. Position Statement on Pharmacologic Treatment of Obstructive Sleep Apnea, 2025.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy is a registered trademark of Novo Nordisk A/S. CPAP is a generic term for continuous positive airway pressure therapy. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly or Novo Nordisk.